{
  "catalysts": [
    {
      "ticker": "ADC",
      "current_price": 70.51,
      "market_cap": "$6.5B",
      "conviction_score": 9,
      "thesis": "Executive Chairman's $1.7M open-market purchase signals high conviction in valuation floor and future growth.",
      "catalyst_details": "Executive Chairman Richard Agree filed Form 4 reporting purchase of 24,000 shares (~$1.7M) on Jan 9, 2026.",
      "absorption_status": "Ignored. Stock is down -0.2% since the purchase, offering entry below the insider's cost basis ($70.67).",
      "earnings_date": "2026-02-10",
      "relative_volume": "0.8x",
      "stop_loss_trigger": "$68.93 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "N/A",
      "recency_proof": "2026-01-09 Form 4 Filing",
      "risk": "Interest rate sensitivity (REIT)",
      "expected_upside": "15% (Target $80) | Target: $73.66",
      "mispricing_evidence": "Price is below the weighted average price paid by the insider ($70.67), indicating an immediate discount.",
      "x_sentiment": "Low",
      "atr_value": 1.05,
      "calculated_stop_loss": 68.93,
      "calculated_target": 73.66
    },
    {
      "ticker": "CRNX",
      "current_price": 53.25,
      "market_cap": "$5.2B",
      "conviction_score": 8,
      "thesis": "Goldman Sachs upgrade to Buy on Jan 12 creates a Tier 1 catalyst that the market has not yet priced in (0% intraday move).",
      "catalyst_details": "Goldman Sachs upgraded CRNX from Neutral to Buy with a $67 price target on January 12, 2026, citing strong commercial potential.",
      "absorption_status": "Unpriced. Stock is trading flat (0.0%) despite a major bank upgrade, suggesting a delayed reaction or market inefficiency.",
      "earnings_date": "2026-02-25",
      "relative_volume": "1.05x",
      "stop_loss_trigger": "$48.62 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "High confidence in analyst impact",
      "recency_proof": "2026-01-12 09:30 EST",
      "risk": "Biotech pipeline volatility",
      "expected_upside": "25% (Target $67) | Target: $62.51",
      "mispricing_evidence": "Stock is unchanged intraday despite a Tier 1 upgrade that typically drives 3-5% immediate flows.",
      "x_sentiment": "Moderate buzz on upgrade",
      "atr_value": 3.09,
      "calculated_stop_loss": 48.62,
      "calculated_target": 62.51
    }
  ]
}